来自官方财务报表的收入、利润与现金流历史。
Regeneron Pharmaceuticals, Inc. 发现、发明、开发、制造和商业化用于治疗全球各种疾病的药物。该公司开发治疗眼科、过敏和炎症、心血管、代谢、神经、传染病和罕见疾病的候选产品；以及癌症、血液系统疾病。它还提供 EYLEA 注射剂，用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿；近视脉络膜新生血管；糖尿病视网膜病变；新生血管性青光眼；早产儿视网膜病变; Dupixent注射液治疗特应性皮炎和哮喘； Libtayo注射液用于治疗转移性或局部晚期皮肤鳞状细胞癌；补充注射治疗杂合子家族性高胆固醇血症（HoFH）；和治疗类风湿性关节炎的 Kevzara 溶液。与拜耳签署了 EYLEA 8 mg 和 EYLEA 的开发和商业化许可和合作协议； Alnylam Pharmaceuticals, Inc. 通过解决眼睛和中枢神经系统中表达的治疗疾病靶标来发现、开发和商业化 RNAi 疾病疗法； Intellia Therapeutics, Inc. 将推进 CRISPR/Cas9 基因编辑技术，用于神经和肌肉疾病疗法的体内治疗开发；豪森制药集团有限公司将获得 GLP-1/GIP 双受体 HS-20094 的开发和商业权； Tessera Therapeutics, Inc.
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $15.5B | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B | $8.5B | $7.9B | $6.7B | $5.9B | $4.9B | $4.1B | $2.8B | $2.1B | $1.4B | $446M | $459M | $379M | $238M | $125M | $63M |
| 毛利 | $13.2B | $12.2B | $12.2B | $12.2B | $10.5B | $13.3B | $7.1B | $7.1B | $6.3B | $5.5B | $4.6B | $3.7B | $2.6B | $1.9B | $1.3B | $442M | $457M | $363M | $238M | $125M | $41M |
| 毛利率% | 84.9% | 85.4% | 86.1% | 93.3% | 86.0% | 83.0% | 84.0% | 90.0% | 93.5% | 93.2% | 93.8% | 90.4% | 92.7% | 92.6% | 93.9% | 99.1% | 99.5% | 95.8% | 99.6% | 100.0% | 64.2% |
| 营业利润（EBIT） | $4.0B | $3.6B | $4.0B | $4.0B | $5.4B | $8.9B | $3.6B | $2.2B | $2.5B | $2.1B | $1.3B | $1.3B | $838M | $760M | $458M | ($205M) | ($97M) | ($74M) | ($90M) | ($114M) | ($107M) |
| 营业利润率% | 25.6% | 24.9% | 28.1% | 30.9% | 44.2% | 55.7% | 42.1% | 28.1% | 37.8% | 35.4% | 27.4% | 30.5% | 29.7% | 36.1% | 33.2% | -46.0% | -21.2% | -19.5% | -37.7% | -91.5% | -169.1% |
| 净利 | $4.3B | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B | $3.5B | $2.1B | $2.4B | $1.2B | $896M | $636M | $348M | $424M | $750M | ($222M) | ($104M) | ($68M) | ($83M) | ($106M) | ($102M) |
| 净利润率 % | 27.9% | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 26.9% | 36.4% | 20.4% | 18.4% | 15.5% | 12.3% | 20.2% | 54.4% | -49.7% | -22.8% | -17.9% | -34.7% | -84.5% | -161.3% |
| EBITDA | $5.8B | $5.8B | $5.3B | $4.0B | $5.3B | $9.7B | $4.1B | $2.4B | $2.7B | $2.2B | $1.4B | $1.3B | $891M | $801M | $495M | ($174M) | ($78M) | ($55M) | ($79M) | ($82M) | ($77M) |
| 每股收益（EPS） | $40.37 | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $3.07 | $3.81 | $6.50 | $-2.45 | $-1.26 | $-0.85 | $-1.05 | $-1.59 | $-1.77 |
| 已发行股数 (M) | 107M | 109M | 115M | 114M | 114M | 112M | 115M | 115M | 115M | 116M | 116M | 115M | 113M | 111M | 115M | 91M | 83M | 80M | 79M | 66M | 58M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 REGN 交互式查看器。 /companies/us/REGN
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms